nature research

Corresponding author(s):	Zhenhua Shao
Last updated by author(s):	Sep 6, 2020

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_					
5	۲a	ŤΙ	ıct	ш	<u>ر</u> د

1016	an statistical analyses, commit that the following items are present in the figure regend, tradic regend, main text, or interious section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
x	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X	A description of all covariates tested
X	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient, AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
x	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

X-ray diffraction data was collected at beamline 41XU at the Spring-8, Hyogo, Japan. X-ray data was indexed, integrated, and scaled using HKL3000. The GnRH1R structure was solved using Phaser in Phenix software suite (version 1.17.1-3660). The structure model was further refined in Coot (0.8.9) and Refmac5 in CCP4 package (7.0.078). Refinement parameters for elagolix ligand were generated using PRODRG web server (http://davapc1.bioch.dundee.ac.uk/prodrg/).

Data analysis

Signaling and binding assays were analyzed using Graphpad Prism 7.0. MODELLER (v9.14102), CDOCKER in the BIOVIA Discovery studio 3.1 (Accelrys Inc., San Diego, CA, USA), CHARMM-GUI web server (http://charmm-gui.org), GROMACS (2019.4) and PROPKA 3.0 simulation package were also used in this study.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The PDB ID, such as 4SOV and 2BFW, used in this study are available in the Protein Data Bank (PDB). Structural data of GnRH1R has been deposited in the PDB with coordinate accession number 7BR3. Sequence of the construct used in this study is listed in Supplementary Figure 1. The source data about signaling assays are provided as a Source Data file. All other data generated or analyzed during the study are included in this article (and supplementary information files) or are

available from the c	corresponding auth	nor on reasonable request.				
E: 1.1						
Field-spe	ecific re	porting				
Please select the o	one below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
🗶 Life sciences		ehavioural & social sciences				
For a reference copy of	f the document with a	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life scie	nces stu	ıdy design				
All studies must di	isclose on these	points even when the disclosure is negative.				
Sample size	degree because accumulation m	e because of radiation damage. The final dataset (100% completeness) are from 23 crystals after calculation and analysis. For IP nulation measurement and binding assay, experiments were performed as at least three independent experiments, each run at least in ate. The size was chosen in order to obtain an accurate S.D. or S.E. for reported values.				
Data exclusions	No data was exc	cluded from the analyses.				
Replication	successfully. Th	Protein samples were purified from different purification batch and were performed for crystallization. The procedures were repeated successfully. The final crystallography dataset are from 23 crystals, demonstrating reproducibility. The biochemical experiments in this study have been repeated by three independent experiments, and those finding are reliably reproduced.				
Randomization	Randomization	is not relevant to this study, as protein, crystal samples and our experiments did not involve choosing.				
Blinding	Randomization	is not relevant to this study, because the data collection and analysis are not biased by investigators.				
We require informat	tion from authors a	Decific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & ex	xperimental s	ystems Methods				
n/a Involved in t	the study	n/a Involved in the study				
-1-	Antibodies ChIP-seq					
	Eukaryotic cell lines X Flow cytometry					
	ology and archaeol and other organism	— <u>!—</u>				
	esearch participant					
Clinical da						
Dual use r	research of concer	n				
- '	11.15					
Eukaryotic o	cell lines					
Policy information	n about <u>cell lines</u>					
Cell line source(s)		Sf9 cells, Expression systems, Cat. 94011S. HEK293 cells, ATCC, CRL-1573. COS-7 cells, ATCC, CRL-1651.				
Authentication	Authentication The cell lines are maintained by the supplier and verified by short random repeat (STR) profiling method. study are all from low-passage cell lines. Thier morphology and growth curve analysis are further checked and cell counter respectively by investigators in this study.					
Mycoplasma conta	amination	The cell lines used in this study were negative for mycoplasma contamination.				

No commonly misidentified cell lines were used.

Commonly misidentified lines (See <u>ICLAC</u> register)